Latest news
Almac Discovery and Debiopharm International SA Announce a Licensing Agreement for the Development of a Novel Wee-1 Inhibitor
Debiopharm International SA Announces Completion of Enrollment in Phase I/II Clinical Trial with Debio 1143 in SCCHN
Debiopharm International SA Announces Results from Phase I Dose-Escalation Study of Debio 1347/CH5183284
Debiopharm International SA Enters the Field of Antibody-Drug Conjugates Through Acquisition of Phase II Asset from ImmunoGen
BC Platforms Closes USD $10 million Series B Financing led by Debiopharm and Tesi to accelerate knowledge platform development
Debiopharm International uses cutting-edge ClinTrial App mobile application from ClinOne in clinical study
Stay informed
Don't miss any latest news and announcements on Debiopharm Investment, subscribe to our newsletter.